Clinical Research Directory

Inclusion Criteria: * Patients sign the informed consent * Patient had a prostate biopsy performed by Dr. Mark with the Artemis device and has adenocarcinoma of the prostate * Patient elects to undergo active surveillance * Clinical stage T2c or less * Gleason grade 3+4 or less * PSA \< 25 * Geographically able to have study visits at the University of California, Los Angeles (UCLA) Clinical Research Unit * Subjects are willing to not consume lycopene, green tea or pomegranate supplements or pomegranate juice during the 1-year study * If subjects are randomized to the control group they agree to not consume fish oil capsules during the 1-year study Exclusion Criteria: * Diagnostic prostate biopsy with only 1 core with cancer and \< 5% of tissue from that core involved with cancer * Patient has taken finasteride or dutasteride during the prior year * Patient has taken fish oil during the prior 3 months * Patient had prior treatment for prostate cancer (surgery, radiation, local ablative therapy, anti-androgen therapy or androgen deprivation therapy) * Patient has other medical conditions that exclude him from undergoing a repeat prostate biopsy at 1-year * Patient has allergy to fish